{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:56:35Z","timestamp":1785455795565,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":1623,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1093\/annonc\/mdv144","type":"journal-article","created":{"date-parts":[[2015,3,19]],"date-time":"2015-03-19T00:51:36Z","timestamp":1426726296000},"page":"1230-1237","source":"Crossref","is-referenced-by-count":71,"title":["Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors"],"prefix":"10.1016","volume":"26","author":[{"given":"E.G.","family":"Chiorean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.I.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.B.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.P.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.E.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv144_bb0010","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv144_bb0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/j.1460-2075.1996.tb00359.x","article-title":"A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases","volume":"15","author":"Joukov","year":"1996","journal-title":"Embo J"},{"key":"10.1093\/annonc\/mdv144_bb0020","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc863","article-title":"Metastasis: lymphangiogenesis and cancer metastasis","volume":"2","author":"Stacker","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdv144_bb0025","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/sj.jid.5700464","article-title":"New insights into the molecular control of the lymphatic vascular system and its role in disease","volume":"126","author":"Cueni","year":"2006","journal-title":"J Invest Derm"},{"key":"10.1093\/annonc\/mdv144_bb0030","first-page":"1323","article-title":"A phase 1 study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma","volume":"9","author":"Posey","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv144_bb0035","doi-asserted-by":"crossref","first-page":"143s)","DOI":"10.1200\/jco.2007.25.18_suppl.3523","article-title":"Phase I and DCE-MRI evaluation of CPD791, a di-Fab PEG conjugate that inhibits VEGFR2","volume":"25","author":"Jayson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv144_bb0040","first-page":"5209","article-title":"Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors","volume":"59","author":"Prewett","year":"1999","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv144_bb0045","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbrc.2006.04.119","article-title":"Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2","volume":"345","author":"Miao","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdv144_bb0050","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1517\/14712598.2013.810717","article-title":"Targeted inhibition of VEGF receptor 2: an update on ramucirumab","volume":"13","author":"Clarke","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1093\/annonc\/mdv144_bb0055","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv144_bb0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/annonc\/mdv144_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ccr.2005.01.017","article-title":"Focus on lymphangiogenesis in tumor metastasis","volume":"7","author":"Achen","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdv144_bb0070","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/0008-5472.CAN-12-4539","article-title":"VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis","volume":"73","author":"Alitalo","year":"2013","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv144_bb0075","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1093\/annonc\/mdv144_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv144_bb0085","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv144_bb0090","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv144_bb0095","doi-asserted-by":"crossref","first-page":"e77117","DOI":"10.1371\/journal.pone.0077117","article-title":"The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer","volume":"8","author":"Lieu","year":"2013","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdv144_bb0100","doi-asserted-by":"crossref","first-page":"6957","DOI":"10.1158\/1078-0432.CCR-13-0926","article-title":"Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)","volume":"19","author":"Nixon","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv144_bb0105","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3531","article-title":"Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): analysis of the phase III MAX study","volume":"29","author":"Weickhardt","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/6\/1230\/16699972\/mdv144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:49:27Z","timestamp":1624520967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0923753419318149"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv144","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}